Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells

Abstract

Background: miR-155 acts as a ubiquitous oncogene in major classes of human cancers and is a potential target for therapeutic intervention. However, the role of miR-155 in multiple myeloma is poorly understood.

Methods: To explore the role of miR-155 in multiple myeloma, we assessed the influence of tiny seed-targeting anti-miR-155 (t-anti-miR-155) on multiple myeloma cell line (RPMI-8266) viability and apoptosis in vitro.

Results: t-anti-miR-155 significantly inhibited multiple myeloma cell proliferation, migration, and colony formation. Additionally, t-anti-miR-155 significantly increased CD19 positive cell numbers, which are novel biomarkers for multiple myeloma and suppressor of cytokine signaling 1(SOCS1) was shown to be a target gene for miR-155 in multiple myeloma. Finally, the miR-155 signaling pathway was investigated by KEGG assay.

Conclusion: miR-155 in RPMI-8266 cells is a critical oncomiR in multiple myeloma and seed-targeting t-anti-miR-155 might be a novel strategy for miR-155-based therapeutics.

• miR-155
• multiple myeloma
• seed targeting
• tiny anti-miRNA

Declaration of interest

The authors have no conflicts of interest to declare. This work was supported by grants from the National Natural Science Foundation of China (no. 81170496), Fundamental Research Funds for the Central Universities (no. 21609406), the Natural Science Foundation of Guangdong Province (S2013010013462), and Key Discipline Construction Foundation of Jinan University.